BioCentury
ARTICLE | Company News

AmDerma, Oculus deal

July 2, 2012 7:00 AM UTC

Oculus granted AmDerma exclusive rights to develop and commercialize compounds using Oculus' Microcyn technology for dermatology indications, including acne. AmDerma will have rights to the compounds in the U.S. and India, with a right of first refusal in EU, Canada, Brazil and Japan. Oculus will retain rights in all other territories. The company will receive an upfront payment and is eligible for clinical and regulatory milestones and double-digit royalties. Details were not disclosed. ...